You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

non MSI-H/dMMR

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Trial (S095029, Pembrolizumab 200 mg)

Not yet recruiting
  • MSI-H/dMMR Gastroesophageal-junction Cancer
  • MSI-H/dMMR Gastric Cancer
  • (no location specified)
Oct 30, 2023

Registry Study in MSI/dMMR Solid Tumors

Not yet recruiting
  • DMMR Cancer
  • +2 more
    • (no location specified)
    Aug 21, 2023

    Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H

    Recruiting
    • Colorectal Cancer
      • Shanghai, China
        Fudan University Shanghai Cancer Center
      Oct 18, 2023

      Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)

      Not yet recruiting
      • Gastric
      • Colorectal Adenocarcinoma
      • Shenyang, Liaoning, China
        Liaoning Cancer Hospital & Institute
      Nov 1, 2023

      dMMR Colorectal Cancer Trial in Beijing (Cadonilimab)

      Recruiting
      • dMMR Colorectal Cancer
      • Beijing, Beijing, China
        National Cancer Center/Cancer Hospital, Chinese Academy of Medic
      Apr 13, 2023

      Neoadjuvant Envafolimab in Resectable and Locally Advanced

      Not yet recruiting
      • Locally Advanced Rectal Carcinoma
      • MSI-High
      • (no location specified)
      Dec 9, 2022

      Melanoma Stage IV, Unresectable Melanoma, NSCLC Stage IV Trial in Ramat Gan (Fecal Microbial Transplantation by capsules)

      Recruiting
      • Melanoma Stage IV
      • +2 more
      • Fecal Microbial Transplantation by capsules
      • Ramat Gan, Israel
        Sheba Medical Center
      Aug 9, 2021

      Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

      Not yet recruiting
      • Colorectal Cancer
      • +3 more
      • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
      • ZhengZhou, Henan, China
        Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
      Jun 18, 2023

      Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

      Not yet recruiting
      • Adenocarcinoma - GEJ
      • Gastric Adenocarcinoma
      • (no location specified)
      Sep 26, 2023

      Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (PD-1 inhibitor)

      Recruiting
      • Gastric or Gastroesophageal Junction Adenocarcinoma
      • PD-1 inhibitor
      • Guangzhou, China
        Sun Yat-sen University Cancer Center
      Aug 9, 2023

      Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

      Not yet recruiting
      • Multiple Cancer
      • Colorectal Cancer
      • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
      • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
      • (no location specified)
      Aug 20, 2023

      MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)

      Not yet recruiting
      • MSI-H Colorectal Cancer
      • +3 more
      • (no location specified)
      Apr 23, 2023

      Colonic Tumors Trial (Dostarlimab, CAPEOX, FOLFOX)

      Not yet recruiting
      • Colonic Neoplasms
      • Dostarlimab
      • +2 more
      • (no location specified)
      May 3, 2023

      Serplulimab,Gastric Cancer, Adjuvant Therapy Trial in Shanghai (Serplulimab, Docetaxel, S1)

      Recruiting
      • Serplulimab,Gastric Cancer, Adjuvant Therapy
      • Shanghai, China
        Zhang Zizhen
      Mar 3, 2023

      DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

      Not yet recruiting
      • Endometrial Cancer
      • (no location specified)
      Feb 14, 2023

      MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

      Terminated
      • MSI-H/dMMR Solid Tumor
      • Guangzhou, Guangdong, China
        Sun Yat-Sen University Cancer Center
      Oct 17, 2022

      Tumors, Rectal Trial (Dostarlimab)

      Not yet recruiting
      • Neoplasms, Rectal
      • Dostarlimab
      • (no location specified)
      Feb 2, 2023

      MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

      Not yet recruiting
      • MSI-H
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      May 26, 2023

      Solid Tumor Trial in Beijing (KN035)

      Recruiting
      • Solid Tumor
      • KN035
      • Beijing, Beijing, China
        Peking University Cancer Hospital, Peking University
      Apr 5, 2022

      Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

      Recruiting
      • Colorectal Carcinoma
      • Guangzhou, China
        Sun Yat-sen University
      Dec 29, 2022

      Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

      Not yet recruiting
      • Colorectal Cancer Stage IV
      • +2 more
      • (no location specified)
      Jun 19, 2022

      Rectal Tumors Trial in Cleveland (Pembrolizumab, External beam radiation, Capecitabine)

      Recruiting
      • Rectal Neoplasms
      • Cleveland, Ohio
        Cleveland Clinic, Case Comprehensive Cancer Center
      Jan 25, 2023

      Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

      Active, not recruiting
      • Colorectal Cancer
      • IBI310 (anti-CTLA-4 antibody)
      • Sintilimab(anti-PD-1 antibody)
      • Beijing, China
        Beijing cancer hospital
      Sep 15, 2022

      Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

      Recruiting
      • Colorectal Cancer
      • +3 more
      • Neoadjuvant therapy with PD-L1 inhibitor
      • Guangzhou, Guangdong, China
        the Third Affiliated Hospital of Sun Yat-Sen University
      May 10, 2022

      Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

      Active, not recruiting
      Has Results
      • Colorectal Carcinoma
      • (no location specified)
      Oct 28, 2022